Accountability in Opioid Advertising Act

Bill: 115-s-3420
Sponsor: full_name: Sen. Harris, Kamala D. [D-CA]
Introduced: 2018-09-06
Policy area: Health
Subjects: Civil actions and liability

Consumer affairs

Drug safety, medical device, and laboratory regulation

Drug therapy

Drug trafficking and controlled substances

Drug, alcohol, tobacco use

Fraud offenses and financial crimes

Marketing and advertising

Prescription drugs

Television and film
Latest action: action_date: 2018-09-06
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2018-09-06
action_desc: Introduced in Senate
text: <p><b>Accountability in Opioid Advertising Act</b></p> <p>This bill requires the Food and Drug Administration to prioritize the review of advertising and other promotional materials for drug for serious, life-threatening diseases or conditions or substance use disorders, especially opioids (drugs with effects similar to opium, such as certain pain medications)and drugs used in the treatment of opioid use disorders.</p>

tv_txt: II 115th CONGRESS 2d Session S. 3420 IN THE SENATE OF THE UNITED STATES September 6, 2018 Ms. Harris (for herself and Mr. Gardner ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To require the Food and Drug Administration to prioritize the promotional materials for drugs for serious, life-threatening diseases or conditions or substance use disorders, especially opioid drugs and drugs for medication-assisted treatment, in considering whether promotional materials are false or misleading.

1. Short title This Act may be cited as the Accountability in Opioid Advertising Act . 2. Promotional materials for drugs In enforcing section 303(g) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 333(g) ) and otherwise ensuring that advertising and other promotional materials for drugs approved under section 505 of such Act ( 21 U.S.C. 355 ), including pursuant to section 503C of such Act ( 21 U.S.C. 353c ), are not false or misleading, the Secretary of Health and Human Services shall give priority consideration to advertising and other promotional materials for drugs for serious, life-threatening diseases or conditions or substance use disorders, especially opioid drugs and drugs for medication-assisted treatment.